The recombinant dna technology market size has grown strongly in recent years. It will grow from $913.42 billion in 2025 to $998.83 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to expansion of molecular biology research, increasing incidence of chronic diseases, growth in biologics development, rising academic and government research funding, early commercialization of recombinant therapies.
The recombinant dna technology market size is expected to see strong growth in the next few years. It will grow to $1.41 trillion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing investments in gene therapy development, rising demand for personalized medicine, expansion of CRISPR-based applications, growing focus on sustainable bioproduction, increasing collaboration between academia and industry. Major trends in the forecast period include increasing adoption of gene editing platforms, rising development of recombinant vaccines, growing use of advanced expression systems, expansion of cell and gene therapy pipelines, enhanced focus on scalable biomanufacturing.
The growing advancement of genetically modified crops is projected to drive the expansion of the recombinant DNA technology market in the future. Genetically modified crops are plants that have been intentionally altered at the genetic level using biotechnological methods. Recombinant DNA (rDNA) technology is utilized in the development of genetically modified (GM) crops by isolating genes that provide desired traits, creating recombinant DNA, inserting it into host crop cells, selecting and screening for successful integrations, regenerating transgenic plants, verifying trait expression, conducting field trials, securing regulatory approvals, and ultimately commercializing crops with enhanced characteristics. For example, in December 2023, the United States Department of Agriculture, a US-based government agency, reported that Canada planted 11.7 million hectares of genetically engineered (GE) crops, mainly including canola, soybeans, and corn. This marks a four percent increase from the previous year, largely due to the expansion of canola planting areas. Consequently, the growing development of genetically modified crops is fueling the growth of the recombinant DNA technology market.
Major companies operating in the recombinant DNA technology market are increasingly integrating advanced gene-editing approaches, including clustered regularly interspaced short palindromic repeats (CRISPR)-based recombinant DNA engineering, to improve precision, therapeutic effectiveness, and targeted genome modification. CRISPR-based recombinant DNA engineering is a molecular method that employs a guide ribonucleic acid (RNA) and the Cas9 enzyme to precisely identify and cut specific deoxyribonucleic acid (DNA) sequences, enabling targeted gene correction, controlled DNA insertion, and efficient genomic alteration. For example, in December 2023, Vertex Pharmaceuticals, a United States-based biotechnology company, in collaboration with CRISPR Therapeutics, a Switzerland-based gene-editing biotechnology company, received approval from the United States Food and Drug Administration for Casgevy, a CRISPR-enabled recombinant DNA therapy for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. The therapy edits a patient’s own stem cells to increase fetal hemoglobin production and incorporates features such as targeted DNA cleavage, high-fidelity gene modification, and ex vivo cell processing. Casgevy enhances treatment outcomes by enabling durable gene correction, reducing reliance on conventional therapies, and supporting long-term clinical benefits.
In October 2024, SK bioscience, a South Korea-based vaccine and biotechnology company, acquired IDT Biologika for an undisclosed consideration. Through this acquisition, SK bioscience seeks to expand its global manufacturing footprint, accelerate growth in recombinant vaccines as well as cell and gene therapy, and achieve a doubling of IDT Biologika’s sales by 2028. IDT Biologika is a Germany-based contract development and manufacturing organization that provides services spanning vaccine production, recombinant vaccine development, viral vector manufacturing, and broader biopharmaceutical contract development and manufacturing activities.
Major companies operating in the recombinant dna technology market are Profacgen BioTech Corp, Amgen Inc, Novartis International AG, GenScript Biotech Corporation, Pfizer Inc, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Merck & Co. Inc, Biogen Inc, GlaxoSmithKline PLC, New England Biolabs Inc, Bayer CropScience, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc, bluebird bio Inc, Lonza Group AG, Horizon Discovery Group PLC, Sarepta Therapeutics Inc, Sangamo Therapeutics Inc.
North America was the largest region in the recombinant DNA technology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the recombinant dna technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the recombinant DNA technology market by increasing costs of imported laboratory reagents, cloning vectors, bioreactors, analytical instruments, and specialized consumables used in genetic engineering workflows. Biotechnology hubs in North America and Europe are most affected due to reliance on imported high-value research inputs, while Asia-Pacific faces higher costs for equipment-intensive manufacturing. These tariffs are increasing research and production expenses and extending development timelines. However, they are also encouraging domestic reagent manufacturing, localized bioprocessing infrastructure, and regional supply chain strengthening for critical biotechnology inputs.
The recombinant dna technology market research report is one of a series of new reports that provides recombinant dna technology market statistics, including recombinant dna technology industry global market size, regional shares, competitors with a recombinant dna technology market share, detailed recombinant dna technology market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant dna technology industry. This recombinant dna technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Recombinant DNA technology denotes the fusion of DNA molecules from diverse organisms, integrating them into a host organism to create new genetic combinations beneficial across scientific, medical, agricultural, and industrial domains. This technology plays a pivotal role in addressing health concerns by facilitating the development of novel medications and vaccines.
Within the realm of recombinant DNA technology, key product categories encompass recombinant protein drugs, vaccines, genetically modified crops, expression systems, cell and gene therapy, and gene editing. Notably, recombinant protein drugs serve crucial roles in biochemical analysis and medical diagnostics within human healthcare, including the production of antibodies, medicines, and vaccines. Renowned for their potency and rapid development compared to small molecules, these drugs are considered safer due to their reduced off-target adverse effects. This category comprises components like expression systems and cloning vectors. The extensive applications of recombinant DNA technology span various sectors such as food and agriculture, health and disease management, environmental interventions, and other diverse areas. This technology finds practical usage in biotechnology and pharmaceutical companies, academic and government research institutions, and various other end-use industries. Its impact is notably significant across a wide spectrum of fields and industries.
The recombinant DNA technology market includes revenues earned by entities by expression systems including mammalian, bacteria, yeast, and baculovirus / insect. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The recombinant dna technology market size is expected to see strong growth in the next few years. It will grow to $1.41 trillion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to increasing investments in gene therapy development, rising demand for personalized medicine, expansion of CRISPR-based applications, growing focus on sustainable bioproduction, increasing collaboration between academia and industry. Major trends in the forecast period include increasing adoption of gene editing platforms, rising development of recombinant vaccines, growing use of advanced expression systems, expansion of cell and gene therapy pipelines, enhanced focus on scalable biomanufacturing.
The growing advancement of genetically modified crops is projected to drive the expansion of the recombinant DNA technology market in the future. Genetically modified crops are plants that have been intentionally altered at the genetic level using biotechnological methods. Recombinant DNA (rDNA) technology is utilized in the development of genetically modified (GM) crops by isolating genes that provide desired traits, creating recombinant DNA, inserting it into host crop cells, selecting and screening for successful integrations, regenerating transgenic plants, verifying trait expression, conducting field trials, securing regulatory approvals, and ultimately commercializing crops with enhanced characteristics. For example, in December 2023, the United States Department of Agriculture, a US-based government agency, reported that Canada planted 11.7 million hectares of genetically engineered (GE) crops, mainly including canola, soybeans, and corn. This marks a four percent increase from the previous year, largely due to the expansion of canola planting areas. Consequently, the growing development of genetically modified crops is fueling the growth of the recombinant DNA technology market.
Major companies operating in the recombinant DNA technology market are increasingly integrating advanced gene-editing approaches, including clustered regularly interspaced short palindromic repeats (CRISPR)-based recombinant DNA engineering, to improve precision, therapeutic effectiveness, and targeted genome modification. CRISPR-based recombinant DNA engineering is a molecular method that employs a guide ribonucleic acid (RNA) and the Cas9 enzyme to precisely identify and cut specific deoxyribonucleic acid (DNA) sequences, enabling targeted gene correction, controlled DNA insertion, and efficient genomic alteration. For example, in December 2023, Vertex Pharmaceuticals, a United States-based biotechnology company, in collaboration with CRISPR Therapeutics, a Switzerland-based gene-editing biotechnology company, received approval from the United States Food and Drug Administration for Casgevy, a CRISPR-enabled recombinant DNA therapy for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. The therapy edits a patient’s own stem cells to increase fetal hemoglobin production and incorporates features such as targeted DNA cleavage, high-fidelity gene modification, and ex vivo cell processing. Casgevy enhances treatment outcomes by enabling durable gene correction, reducing reliance on conventional therapies, and supporting long-term clinical benefits.
In October 2024, SK bioscience, a South Korea-based vaccine and biotechnology company, acquired IDT Biologika for an undisclosed consideration. Through this acquisition, SK bioscience seeks to expand its global manufacturing footprint, accelerate growth in recombinant vaccines as well as cell and gene therapy, and achieve a doubling of IDT Biologika’s sales by 2028. IDT Biologika is a Germany-based contract development and manufacturing organization that provides services spanning vaccine production, recombinant vaccine development, viral vector manufacturing, and broader biopharmaceutical contract development and manufacturing activities.
Major companies operating in the recombinant dna technology market are Profacgen BioTech Corp, Amgen Inc, Novartis International AG, GenScript Biotech Corporation, Pfizer Inc, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Merck & Co. Inc, Biogen Inc, GlaxoSmithKline PLC, New England Biolabs Inc, Bayer CropScience, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc, bluebird bio Inc, Lonza Group AG, Horizon Discovery Group PLC, Sarepta Therapeutics Inc, Sangamo Therapeutics Inc.
North America was the largest region in the recombinant DNA technology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the recombinant dna technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the recombinant DNA technology market by increasing costs of imported laboratory reagents, cloning vectors, bioreactors, analytical instruments, and specialized consumables used in genetic engineering workflows. Biotechnology hubs in North America and Europe are most affected due to reliance on imported high-value research inputs, while Asia-Pacific faces higher costs for equipment-intensive manufacturing. These tariffs are increasing research and production expenses and extending development timelines. However, they are also encouraging domestic reagent manufacturing, localized bioprocessing infrastructure, and regional supply chain strengthening for critical biotechnology inputs.
The recombinant dna technology market research report is one of a series of new reports that provides recombinant dna technology market statistics, including recombinant dna technology industry global market size, regional shares, competitors with a recombinant dna technology market share, detailed recombinant dna technology market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant dna technology industry. This recombinant dna technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Recombinant DNA technology denotes the fusion of DNA molecules from diverse organisms, integrating them into a host organism to create new genetic combinations beneficial across scientific, medical, agricultural, and industrial domains. This technology plays a pivotal role in addressing health concerns by facilitating the development of novel medications and vaccines.
Within the realm of recombinant DNA technology, key product categories encompass recombinant protein drugs, vaccines, genetically modified crops, expression systems, cell and gene therapy, and gene editing. Notably, recombinant protein drugs serve crucial roles in biochemical analysis and medical diagnostics within human healthcare, including the production of antibodies, medicines, and vaccines. Renowned for their potency and rapid development compared to small molecules, these drugs are considered safer due to their reduced off-target adverse effects. This category comprises components like expression systems and cloning vectors. The extensive applications of recombinant DNA technology span various sectors such as food and agriculture, health and disease management, environmental interventions, and other diverse areas. This technology finds practical usage in biotechnology and pharmaceutical companies, academic and government research institutions, and various other end-use industries. Its impact is notably significant across a wide spectrum of fields and industries.
The recombinant DNA technology market includes revenues earned by entities by expression systems including mammalian, bacteria, yeast, and baculovirus / insect. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Recombinant DNA Technology Market Characteristics
3. Recombinant DNA Technology Market Supply Chain Analysis
4. Global Recombinant DNA Technology Market Trends and Strategies
5. Recombinant DNA Technology Market Analysis of End Use Industries
7. Global Recombinant DNA Technology Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Recombinant DNA Technology Total Addressable Market (TAM) Analysis for the Market
9. Recombinant DNA Technology Market Segmentation
10. Recombinant DNA Technology Market Regional and Country Analysis
11. Asia-Pacific Recombinant DNA Technology Market
12. China Recombinant DNA Technology Market
13. India Recombinant DNA Technology Market
14. Japan Recombinant DNA Technology Market
15. Australia Recombinant DNA Technology Market
16. Indonesia Recombinant DNA Technology Market
17. South Korea Recombinant DNA Technology Market
18. Taiwan Recombinant DNA Technology Market
19. South East Asia Recombinant DNA Technology Market
20. Western Europe Recombinant DNA Technology Market
21. UK Recombinant DNA Technology Market
22. Germany Recombinant DNA Technology Market
23. France Recombinant DNA Technology Market
24. Italy Recombinant DNA Technology Market
25. Spain Recombinant DNA Technology Market
26. Eastern Europe Recombinant DNA Technology Market
27. Russia Recombinant DNA Technology Market
28. North America Recombinant DNA Technology Market
29. USA Recombinant DNA Technology Market
30. Canada Recombinant DNA Technology Market
31. South America Recombinant DNA Technology Market
32. Brazil Recombinant DNA Technology Market
33. Middle East Recombinant DNA Technology Market
34. Africa Recombinant DNA Technology Market
36. Recombinant DNA Technology Market Competitive Landscape and Company Profiles
37. Recombinant DNA Technology Market Other Major and Innovative Companies
40. Recombinant DNA Technology Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Recombinant DNA Technology Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses recombinant dna technology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for recombinant dna technology? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The recombinant dna technology market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Recombinant Protein Drugs; Vaccines; Genetically Modified Crops; Expression Systems; Cell And Gene Therapy; Gene Editing2) By Component Type: Expression System; Cloning Vector
3) By Application Type: Food And Agriculture; Health And Disease; Environment; Other Application Types
4) By End-Use Type: Biotechnology And Pharmaceutical Companies; Academic And Government Research Institutes; Other End-Use Types
Subsegments:
1) By Recombinant Protein Drugs: Hormones; Growth Factors2) By Vaccines: Recombinant Viral Vaccines; Recombinant Bacterial Vaccines; Subunit Vaccines
3) By Genetically Modified Crops: Herbicide-Tolerant Crops; Insect-Resistant Crops; Nutritionally Enhanced Crop
4) By Expression Systems: Bacterial Expression Systems; Yeast Expression Systems; Mammalian Expression Systems
5) By Cell And Gene Therapy: Cell-Based Therapies; Gene Replacement Therapies; CAR T-Cell Therapies
6) By Gene Editing: CRISPR Or Cas9 Technologies; TALENs (Transcription Activator-Like Effector Nucleases); ZFNs (Zinc Finger Nucleases)
Companies Mentioned: Profacgen BioTech Corp; Amgen Inc; Novartis International AG; GenScript Biotech Corporation; Pfizer Inc; Novo Nordisk A/S; Eli Lilly and Company; Sanofi S.A; Merck & Co. Inc; Biogen Inc; GlaxoSmithKline PLC; New England Biolabs Inc; Bayer CropScience; F. Hoffmann-La Roche Ltd; Regeneron Pharmaceuticals Inc; Gilead Sciences Inc; Vertex Pharmaceuticals Incorporated; CRISPR Therapeutics AG; Editas Medicine Inc; bluebird bio Inc; Lonza Group AG; Horizon Discovery Group PLC; Sarepta Therapeutics Inc; Sangamo Therapeutics Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Recombinant DNA Technology market report include:- Profacgen BioTech Corp
- Amgen Inc
- Novartis International AG
- GenScript Biotech Corporation
- Pfizer Inc
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi S.A
- Merck & Co. Inc
- Biogen Inc
- GlaxoSmithKline PLC
- New England Biolabs Inc
- Bayer CropScience
- F. Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals Inc
- Gilead Sciences Inc
- Vertex Pharmaceuticals Incorporated
- CRISPR Therapeutics AG
- Editas Medicine Inc
- bluebird bio Inc
- Lonza Group AG
- Horizon Discovery Group PLC
- Sarepta Therapeutics Inc
- Sangamo Therapeutics Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 998.83 Billion |
| Forecasted Market Value ( USD | $ 1410 Billion |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
